Follow the Money: Agios Pharmaceuticals, Inc.

by

Follow the Money highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.

Agios Pharmaceuticals, Inc. is a U.S. public pharmaceutical company that develops drugs that target metabolic pathways critical to cancer cell growth, proliferation and survival. As reported in the December 18, 2014 issue of the PharmSource Lead Sheet, Agios raised $253 million in the closing of a secondary public offering.

Corporate Highlights

  • Agios was incorporated in Delaware in August 2007.
  • Corporate Headquarters: Cambridge, Massachusetts – approximately 39,000 square feet of office and laboratory space.
  • As of December 31, 2013, Agios had 96 employees, of whom 76 were engaged in R&D activities.

Sourcing Opportunities

  • Agios plans to use the proceeds to fund clinical and research development activities.
  • The company relies on third parties, such as CROs, clinical data management organizations, medical institutions, and clinical investigators, to conduct clinical trials and preclinical testing.
  • Agios does not own or operate manufacturing facilities and relies on third parties to produce product candidates for preclinical and clinical testing, as well as commercial sale.
  • For all product candidates, the company intends to identify and qualify manufacturers to provide the API and fill-and-finish services prior to submission of any NDA to the FDA.
  • Agios has no sales, marketing or distribution infrastructure.

Business Relationships

  • In April 2010, Agios and Celgene entered into a collaboration to discover and develop oncologic therapies based on Agios’ cancer metabolism research platform. Agios leads discovery, preclinical, and early clinical development for all cancer metabolism programs under the collaboration.1

Pipeline

Product Candidate Indication Dosage Form Status Next Anticipated Step
Targets in Cancer Metabolism Multiple Cancer Types Unknown Discovery TBA
Targets in Rare Genetic Disorders of Metabolism Multiple Monogenic Diseases Unknown Discovery TBA
AG-120
(IDH1 inhibitor)
Hematologic Malignancies Oral Phase I TBA
AG-221
(IDH2 inhibitor)
Hematologic Malignancies Oral Phase I Global registration program in IDH2-mutant positive hematologic malignancies planned to initiate in 2015.
AG-221
(IDH2 inhibitor)
Solid Tumors Oral Phase I TBA
AG-348
(R-type pyruvate kinase activator)
Pyruvate Kinase Deficiency Oral Phase I TBA
AG-120
(IDH1 inhibitor)
Solid Tumors Oral Phase I/II TBA

 

Finances

(In $ thousands) 2013 2012
Revenues 25,548 25,106
R&D Expenditures 54,502 41,037
General & Administrative Expenditures 9,929 7,064
Total Operating Expenses 64,431 48,101
Capital Expenditures 1,294 1,475

1 Agios Pharmaceuticals, Inc. Annual Report, SEC.gov

Contact Information

Agios Pharmaceuticals, Inc. Key Officers
38 Sidney Street, 2nd Floor David Schenkein, MD, CEO
Cambridge, MA 02139, USA Scott Biller PhD, CSO
Phone: 617-649-8600 Chris Bowden, MD, CMO
Web: www.agios.com Shin-San Michael Su PhD, SVP, R&D
Marion Dorsch PhD, VP, Biology

Read more postings by Ryan

Ryan is a Senior Research Analyst at PharmSource. He holds a BS degree in biology, with a minor in chemistry and a BA degree in Spanish, from the University of North Carolina at Chapel Hill. Prior to joining PharmSource, Ryan worked as a Research Technician in the Neuroscience Center of the UNC Chapel Hill School of Medicine, and has been a named author on research publications.

More posts by Ryan Worthen